Aconitum nagarum var. acaule (Finet & Gagnep.) Q. E. Yang

Emodinanthrone (EmodAn) is a MARCH7 stabilizer that inhibits ferroptosis (EC₅₀=70 nM). Emodinanthrone is also a precursor to Emodin (HY-14393) and possesses antibiotic activity. Emodinanthrone directly binds to MARCH7 and blocks its ubiquitination-mediated degradation at the K608 site; this action enhances MARCH7-mediated K48 ubiquitination and degradation of NCOA4, as well as its regulation of the intracellular localization of TFR1 via K63 ubiquitination, thereby reducing the intracellular labile iron pool and blocking ferroptosis. Emodinanthrone demonstrates in vivo cardioprotective effects and exhibits a favorable safety profile. Emodinanthrone is applicable to research on ferroptosis-related cardiovascular diseases, including Doxorubicin (HY-15142A)-induced cardiomyopathy and myocardial ischemia-reperfusion injury.

Ducloudine C is an alkaloid present in the roots of Aconitum duclouxii with antifungal activity. Ducloudine C has an MIC of 128 μg/mL against Candida albicans.

Glucofrangulin is an active principle. Glucofrangulin can be isolated from Rhamnus frangula.

Pro-xylane (Standard) is the analytical standard of Pro-xylane. This product is intended for research and analytical applications. Emodinanthrone (EmodAn) is a MARCH7 stabilizer that inhibits ferroptosis (EC₅₀=70 nM). Emodinanthrone is also a precursor to Emodin (HY-14393) and possesses antibiotic activity. Emodinanthrone directly binds to MARCH7 and blocks its ubiquitination-mediated degradation at the K608 site; this action enhances MARCH7-mediated K48 ubiquitination and degradation of NCOA4, as well as its regulation of the intracellular localization of TFR1 via K63 ubiquitination, thereby reducing the intracellular labile iron pool and blocking ferroptosis. Emodinanthrone demonstrates in vivo cardioprotective effects and exhibits a favorable safety profile. Emodinanthrone is applicable to research on ferroptosis-related cardiovascular diseases, including Doxorubicin (HY-15142A)-induced cardiomyopathy and myocardial ischemia-reperfusion injury.